Biocartis, a molecular diagnostic firm has entered into a collaboration agreement with Merck to develop and commercialise new liquid biopsy RAS biomaker test to treat patients with metastatic colorectal cancer (mCRC).
The test will be developed on Biocartis automated molecular system Idylla, which is said to provide accurate molecular information from virtually any biological sample in almost any setting.
The Idylla system is an automated sample-to-result PCR-based molecular diagnostics system, which carries out sensitive molecular diagnostic tests.
The Idylla RAS test will detect an extended panel of RAS mutations with two cartridges.
Through this collaboration Merck will have more metastatic colorectal cancer patients gain access to liquid biopsy RAS testing, regardless of their geographical location.